gopubmed logo
find other proteinsAll proteins
GoPubMed Proteins lists recent and important papers and reviews for proteins. Page last changed on 02 Apr 2015.

Monoamine oxidase A

Monoamine Oxidase, MAO
enzyme involved in the oxidative deamination of biogenic and xenobiotic amines [RGD, Feb 2006] (from NCBI)
Top mentioned proteins: MAO-B, CAN, HAD, ACID, V1a
Papers on Monoamine Oxidase
History and Perspectives of A2A Adenosine Receptor Antagonists as Potential Therapeutic Agents.
Varani et al., Ferrara, Italy. In Med Res Rev, 27 Apr 2015
This approach is based on the optimization of the affinity and/or functional activity of the examined compounds toward multiple targets, such as A1 /A2A ARs and monoamine oxidase-B (MAO-B), both closely implicated in the pathogenesis of PD.
Indanones As High-Potency Reversible Inhibitors of Monoamine Oxidase.
Petzer et al., Potchefstroom, South Africa. In Chemmedchem, 27 Apr 2015
UNASSIGNED: Recent reports document that α-tetralone (3,4-dihydro-2H-naphthalen-1-one) is an appropriate scaffold for the design of high-potency monoamine oxidase (MAO) inhibitors.
Molecular Mechanism of Monoamine Oxidase A Gene Regulation under Inflammation and Ischemia-like Conditions: Key Roles of the Transcription Factors GATA2, Sp1 and TBP.
Mahapatra et al., Chennai, India. In J Neurochem, 25 Apr 2015
UNASSIGNED: Monoamine oxidase A (MAOA) plays important roles in the pathogenesis of several neurological and cardiovascular disorders.
Involvement of endothelins in DOCA-salt hypertension through the modulation of noradrenergic transmission in the rat posterior hypothalamus.
Vatta et al., Buenos Aires, Argentina. In Exp Physiol, 25 Apr 2015
We assessed the effects of ET-1 and ET-3 on tyrosine hydroxylase activity and expression, neuronal noradrenaline (NA) release, neuronal NA transporter (NAT) activity and expression, monoamine oxidase activity, and NA endogenous content and utilization (as a marker of turn-over) in the posterior hypothalamus of DOCA-Salt hypertensive rats.
An Analysis of the Influence of Selected Genetic and Hormonal Factors on the Occurrence of Depressive Symptoms in Late-Reproductive-Age Women.
Grochans et al., Szczecin, Poland. In Int J Environ Res Public Health, Dec 2014
CONCLUSIONS: (1) The presence of the s/s genotype of the 5-HTTLPR polymorphism in the serotonin transporter promoter region and the 3/3 genotype of the 30-bp VNTR polymorphism in the monoamine oxidase A promoter region does not contribute to the development of depressive symptoms in late-reproductive-age women.
Biomarkers in the diagnosis of ADHD--promising directions.
Scassellati et al., Syracuse, United States. In Curr Psychiatry Rep, Nov 2014
Interesting data come from the noradrenergic system (norepinephrine transporter, norepinephrine, 3-methoxy-4-hydroxyphenylglycol, monoamine oxidase, neuropeptide Y) for their altered peripheral levels, their association with neuropsychological tasks, symptomatology, drugs effect and brain function.
Adjuvant therapies for HIV-associated neurocognitive disorders.
Douglas et al., Philadelphia, United States. In Ann Clin Transl Neurol, Nov 2014
Multiple adjuvant therapies with various mechanisms of action have been studied (N-methyl D-aspartate [NMDA]-receptor antagonists, MAO-B inhibitors, tetracycline-class antibiotics, and others), but none have shown a clear positive effect in HAND.
Long-term effectiveness of dopamine agonists and monoamine oxidase B inhibitors compared with levodopa as initial treatment for Parkinson's disease (PD MED): a large, open-label, pragmatic randomised trial.
Clarke et al., In Lancet, Oct 2014
BACKGROUND: Whether initial treatment for Parkinson's disease should consist of levodopa, dopamine agonists, or monoamine oxidase type B inhibitors (MAOBI) is uncertain.
GABA from reactive astrocytes impairs memory in mouse models of Alzheimer's disease.
Lee et al., Taejŏn, South Korea. In Nat Med, Aug 2014
Here, we show that reactive astrocytes aberrantly and abundantly produce the inhibitory gliotransmitter GABA by monoamine oxidase-B (Maob) and abnormally release GABA through the bestrophin 1 channel.
Pharmacological treatment of Parkinson disease: a review.
Lang et al., Hamilton, Canada. In Jama, May 2014
RESULTS: Although levodopa is the most effective medication available for treating the motor symptoms of Parkinson disease, in certain instances (eg, mild symptoms, tremor as the only or most prominent symptom, aged <60 years) other medications (eg, monoamine oxidase type B inhibitors [MAOBIs], amantadine, anticholinergics, β-blockers, or dopamine agonists) may be initiated first to avoid levodopa-related motor complications.
EMSAM (deprenyl patch): how a promising antidepressant was underutilized.
Henderson et al., New York City, United States. In Neuropsychiatr Dis Treat, 2013
The EMSAM patch is a unique monoamine oxidase inhibitor (MAOI) being the only antidepressant utilizing a transdermal delivery system.
[Irreversible monoamine oxidase inhibitors (IMAOI) to treat depressive disorders - limited use at present in Flanders].
De Fruyt et al., In Tijdschr Psychiatr, 2013
BACKGROUND: Irreversible monoamine oxidase inhibitors (imaoi) are rarely used in Flanders.
Genetic mediators of neurocognitive outcomes in survivors of childhood acute lymphoblastic leukemia.
Pui et al., Memphis, United States. In J Clin Oncol, 2013
Polymorphisms in monoamine oxidase (T1460CA) were associated with increased attention variability (P = .03).
Lysine-specific demethylase 1 is a therapeutic target for fetal hemoglobin induction.
Tanabe et al., Ann Arbor, United States. In Nat Med, 2013
We show here that lysine-specific demethylase 1 (LSD1) inhibition by RNAi in human erythroid cells or by the monoamine oxidase inhibitor tranylcypromine in human erythroid cells or β-type globin-transgenic mice enhances γ-globin expression.
Genetic factors in anxiety disorders.
Maron et al., Würzburg, Germany. In Mod Trends Pharmacopsychiatri, 2012
Presently available clinical genetic studies point to a considerable heritability of anxiety disorders (30-67%), with multiple vulnerability genes such as 5-HT1A, 5-HTT, MAO-A, COMT, CCK-B, ADORA2A, CRHR1, FKBP5, ACE, RGS2/7 and NPSR1 suggested by molecular genetic association studies.
Apolipoprotein E influences melatonin biosynthesis by regulating NAT and MAOA expression in C6 cells.
Zhou et al., Hefei, China. In J Pineal Res, 2012
A higher level of melatonin was demonstrated in cultured ApoE4-C6 cells than in ApoE3-C6 cells. NAT was up-regulated in ApoE4-C6 cells compared with ApoE3-C6 cells, and MAOA and MAOB expression decreased in ApoE4-C6 cells.
²H kinetic isotope effects and pH dependence of catalysis as mechanistic probes of rat monoamine oxidase A: comparisons with the human enzyme.
Edmondson et al., Atlanta, United States. In Biochemistry, 2011
Rat MAO A exhibits functional properties similar but not identical with those of the human enzyme, providing additional support for C-H bond cleavage via a polar nucleophilic mechanism
Topological probes of monoamine oxidases A and B in rat liver mitochondria: inhibition by TEMPO-substituted pargyline analogues and inactivation by proteolysis.
Edmondson et al., Atlanta, United States. In Biochemistry, 2011
investigation of topological orientation of MAO-A (and MAO-B) in liver mitochondrial membranes
High-level expression and purification of rat monoamine oxidase A (MAO A) in Pichia pastoris: comparison with human MAO A.
Edmondson et al., Atlanta, United States. In Protein Expr Purif, 2010
Although approximately 90% identical in sequence to human MAO A, rat MAO A is a more efficient catalyst for amine neurotransmitter oxidation.
Gonadectomy and hormone replacement exert region- and enzyme isoform-specific effects on monoamine oxidase and catechol-O-methyltransferase activity in prefrontal cortex and neostriatum of adult male rats.
Kritzer et al., Stony Brook, United States. In Neuroscience, 2010
significant effects of hormone replacement and gonadectomy on catechol-O-methyltransferase and monoamine oxidase isoforms in both striatum and cortex
share on facebooktweetadd +1mail to friends